Global Systemic Lupus Erythematosus (SLE) Drugs Market Research Report 2023

Publication ID:

PB502234498

Publication Date:

February 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
Highlights
The global Systemic Lupus Erythematosus (SLE) Drugs market was valued at US$ 163.3 million in 2022 and is anticipated to reach US$ 266.8 million by 2029, witnessing a CAGR of 6.8% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Systemic Lupus Erythematosus (SLE) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Systemic Lupus Erythematosus (SLE) Drugs.
The Systemic Lupus Erythematosus (SLE) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Systemic Lupus Erythematosus (SLE) Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Systemic Lupus Erythematosus (SLE) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Anthera Pharmaceuticals
GSK
ImmuPharma
Johnson & Johnson
Segment by Type
Corticosteroids
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Anti-Inflammatories
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Antimalarials
BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
Immunosuppressive Agents/Immune Modulators
Anticoagulants
Segment by Application
Intravenous
Sub-Cutaneous
Oral
Topical
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Systemic Lupus Erythematosus (SLE) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Systemic Lupus Erythematosus (SLE) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Systemic Lupus Erythematosus (SLE) Drugs Market Overview
1.1 Product Overview and Scope of Systemic Lupus Erythematosus (SLE) Drugs
1.2 Systemic Lupus Erythematosus (SLE) Drugs Segment by Type
1.2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Corticosteroids
1.2.3 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
1.2.4 Anti-Inflammatories
1.2.5 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
1.2.6 Antimalarials
1.2.7 BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
1.2.8 Immunosuppressive Agents/Immune Modulators
1.2.9 Anticoagulants
1.3 Systemic Lupus Erythematosus (SLE) Drugs Segment by Application
1.3.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Value by Application: (2023-2029)
1.3.2 Intravenous
1.3.3 Sub-Cutaneous
1.3.4 Oral
1.3.5 Topical
1.4 Global Systemic Lupus Erythematosus (SLE) Drugs Market Size Estimates and Forecasts
1.4.1 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue 2018-2029
1.4.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales 2018-2029
1.4.3 Global Systemic Lupus Erythematosus (SLE) Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Systemic Lupus Erythematosus (SLE) Drugs Market Competition by Manufacturers
2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Systemic Lupus Erythematosus (SLE) Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Systemic Lupus Erythematosus (SLE) Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Systemic Lupus Erythematosus (SLE) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Systemic Lupus Erythematosus (SLE) Drugs, Product Type & Application
2.7 Systemic Lupus Erythematosus (SLE) Drugs Market Competitive Situation and Trends
2.7.1 Systemic Lupus Erythematosus (SLE) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Systemic Lupus Erythematosus (SLE) Drugs Players Market Share by Revenue
2.7.3 Global Systemic Lupus Erythematosus (SLE) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Systemic Lupus Erythematosus (SLE) Drugs Retrospective Market Scenario by Region
3.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Systemic Lupus Erythematosus (SLE) Drugs Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Region: 2018-2029
3.2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Region: 2018-2023
3.2.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Region: 2024-2029
3.3 Global Systemic Lupus Erythematosus (SLE) Drugs Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Region: 2018-2029
3.3.1 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Region: 2018-2023
3.3.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Region: 2024-2029
3.4 North America Systemic Lupus Erythematosus (SLE) Drugs Market Facts & Figures by Country
3.4.1 North America Systemic Lupus Erythematosus (SLE) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Systemic Lupus Erythematosus (SLE) Drugs Sales by Country (2018-2029)
3.4.3 North America Systemic Lupus Erythematosus (SLE) Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Systemic Lupus Erythematosus (SLE) Drugs Market Facts & Figures by Country
3.5.1 Europe Systemic Lupus Erythematosus (SLE) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Systemic Lupus Erythematosus (SLE) Drugs Sales by Country (2018-2029)
3.5.3 Europe Systemic Lupus Erythematosus (SLE) Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Systemic Lupus Erythematosus (SLE) Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Systemic Lupus Erythematosus (SLE) Drugs Market Facts & Figures by Country
3.7.1 Latin America Systemic Lupus Erythematosus (SLE) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Systemic Lupus Erythematosus (SLE) Drugs Sales by Country (2018-2029)
3.7.3 Latin America Systemic Lupus Erythematosus (SLE) Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Systemic Lupus Erythematosus (SLE) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Systemic Lupus Erythematosus (SLE) Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Systemic Lupus Erythematosus (SLE) Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Systemic Lupus Erythematosus (SLE) Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Type (2018-2029)
4.1.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Type (2018-2023)
4.1.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Type (2024-2029)
4.1.3 Global Systemic Lupus Erythematosus (SLE) Drugs Sales Market Share by Type (2018-2029)
4.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Type (2018-2029)
4.2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Type (2018-2023)
4.2.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Type (2024-2029)
4.2.3 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Systemic Lupus Erythematosus (SLE) Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Application (2018-2029)
5.1.1 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Application (2018-2023)
5.1.2 Global Systemic Lupus Erythematosus (SLE) Drugs Sales by Application (2024-2029)
5.1.3 Global Systemic Lupus Erythematosus (SLE) Drugs Sales Market Share by Application (2018-2029)
5.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Application (2018-2029)
5.2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Application (2018-2023)
5.2.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue by Application (2024-2029)
5.2.3 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Systemic Lupus Erythematosus (SLE) Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Anthera Pharmaceuticals
6.1.1 Anthera Pharmaceuticals Corporation Information
6.1.2 Anthera Pharmaceuticals Description and Business Overview
6.1.3 Anthera Pharmaceuticals Systemic Lupus Erythematosus (SLE) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Anthera Pharmaceuticals Systemic Lupus Erythematosus (SLE) Drugs Product Portfolio
6.1.5 Anthera Pharmaceuticals Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Systemic Lupus Erythematosus (SLE) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Systemic Lupus Erythematosus (SLE) Drugs Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 ImmuPharma
6.3.1 ImmuPharma Corporation Information
6.3.2 ImmuPharma Description and Business Overview
6.3.3 ImmuPharma Systemic Lupus Erythematosus (SLE) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 ImmuPharma Systemic Lupus Erythematosus (SLE) Drugs Product Portfolio
6.3.5 ImmuPharma Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Corporation Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Systemic Lupus Erythematosus (SLE) Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Johnson & Johnson Systemic Lupus Erythematosus (SLE) Drugs Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Systemic Lupus Erythematosus (SLE) Drugs Industry Chain Analysis
7.2 Systemic Lupus Erythematosus (SLE) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Systemic Lupus Erythematosus (SLE) Drugs Production Mode & Process
7.4 Systemic Lupus Erythematosus (SLE) Drugs Sales and Marketing
7.4.1 Systemic Lupus Erythematosus (SLE) Drugs Sales Channels
7.4.2 Systemic Lupus Erythematosus (SLE) Drugs Distributors
7.5 Systemic Lupus Erythematosus (SLE) Drugs Customers
8 Systemic Lupus Erythematosus (SLE) Drugs Market Dynamics
8.1 Systemic Lupus Erythematosus (SLE) Drugs Industry Trends
8.2 Systemic Lupus Erythematosus (SLE) Drugs Market Drivers
8.3 Systemic Lupus Erythematosus (SLE) Drugs Market Challenges
8.4 Systemic Lupus Erythematosus (SLE) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Anthera Pharmaceuticals
GSK
ImmuPharma
Johnson & Johnson

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂